Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivosidenib and Nivolumab in IDH1 Mutated R/R AML and High Risk MDS
NCT04044209Phase 2Withdrawn
- Sponsor
- Yale University
- Start
- Feb 2020
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ivosidenib in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by Yale University. Planned start Feb 2020; status: withdrawn.
02
Drugs
ivosidenib
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT04044209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04044209.